Immatics (IMTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Immatics (IMTX) is set to report its Q1 2025 earnings on August 12, expecting a loss of ($0.38) per share with projected revenue of $13.05 million.
• After a recent earnings report in May, where Immatics beat expectations with revenue of $20.12 million, analysts predict the company will continue to experience a negative EPS trend for the current and next fiscal years.
• Institutional investors hold 64.41% of Immatics stock, with Bank of America recently increasing its position by 166%, signaling growing confidence in the company.

Immatics (NASDAQ:IMTX - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $13.05 million for the quarter.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. The company had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative net margin of 14.73% and a negative return on equity of 4.52%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Price Performance

Shares of IMTX stock traded down $0.14 on Friday, hitting $6.18. The stock had a trading volume of 189,902 shares, compared to its average volume of 354,574. The business has a 50 day moving average of $6.00 and a 200 day moving average of $5.17. The stock has a market cap of $751.18 million, a price-to-earnings ratio of -36.35 and a beta of 0.93. Immatics has a 12-month low of $3.30 and a 12-month high of $13.09.

Institutional Investors Weigh In On Immatics

A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE lifted its position in Immatics N.V. (NASDAQ:IMTX - Free Report) by 166.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,575 shares of the company's stock after buying an additional 2,231 shares during the quarter. Bank of America Corp DE's holdings in Immatics were worth $25,000 at the end of the most recent quarter. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IMTX. Wall Street Zen lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft began coverage on shares of Immatics in a research report on Wednesday, May 28th. They set a "buy" rating and a $10.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $14.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.